Zoledronic acid monohydrate
SIGMA/SML0223 - ≥98% (HPLC)
Synonym: P,P′-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate; Zoledronate monohydrate; [1-
CAS Number: 165800-06-6
Empirical Formula (Hill Notation): C5H10N2O7P2·H2O
Molecular Weight: 290.10
MDL Number: MFCD08448695
Linear Formula: C5H10N2O7P2·H2O
Product Type: Chemical
assay | ≥98% (HPLC) |
color | white to beige |
form | powder |
InChI | 1S/C5H10N2O7P2.H2O/c8-5(1 |
InChI key | FUXFIVRTGHOMSO-UHFFFAOYSA |
Quality Level | 100 ![]() |
SMILES string | O.OC(Cn1ccnc1)(P(O)(O)=O) |
solubility | H2O: ≥2 mg/mL |
storage condition | desiccated |
protect from light | |
storage temp. | 2-8°C |
Application: | Zoledronic acid monohydrate has been used: • as an inhibitor for cell proliferation in glioblastoma, breast cancer tumor and prostate cancer cell line LAPC4 • as a conjugate with • as an inhibitor for farnesyl diphosphate synthase enzyme in glioblastoma cells |
Biochem/physiol Actions: | Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget′s disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones. |
Packaging: | 10, 50 mg in glass bottle |
Symbol | ![]() |
Signal word | Warning |
Hazard statements | H315 - H319 - H335 |
Precautionary statements | P302 + P352 - P305 + P351 + P338 |
Hazard Codes | Xi |
Risk Statements | 36/37/38 |
Safety Statements | 26 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC) |
Storage Temp. | 2-8°C |
UNSPSC | 12352204 |